Aviomarin

Quick links to important sections

Aviomarin

Method of action: Antiemetic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aviomarin

Quick Facts

Property Description
Active ingredient Dimenhydrinate (INN)
Form Oral preparations (Tablet)
Pharmacological class Antihistamine (H1-receptor antagonist), Anti-emetic agent
Common use Prevention and relief of motion sickness (kinetosis)
Origin Synthetic compound

Defining Aviomarin: Classification and General Purpose

Aviomarin is a recognized brand name for the synthetic compound Dimenhydrinate, which functions as a first-generation antihistamine and a dedicated anti-emetic agent. The drug's primary therapeutic purpose is the prevention and general relief of symptoms associated with motion sickness (kinetosis). Dimenhydrinate is globally categorized as an H1-receptor antagonist, a classification noted for its capacity to reduce the effects of histamine and acetylcholine. This action helps to mitigate travel-related discomfort, making the product a frequent choice for travelers who experience symptoms like nausea and vertigo during vehicle movement.

Composition and Entity Form: What is Dimenhydrinate Made Of?

The active substance, Dimenhydrinate (INN), is chemically a unique combination product presented as an equimolar salt. It is composed of two distinct substances: Diphenhydramine, which provides the primary anti-nausea action, and 8-Chlorotheophylline, which is added to mitigate the pronounced sedative effects of the first component. This salt composition is a distinguishing feature of the Dimenhydrinate entity. Dimenhydrinate is typically supplied as an oral preparation, most commonly in the form of a tablet, intended for oral route of administration. Dimenhydrinate is an established antiemetic agent.

The High-Level Function: How Does Aviomarin Generally Help?

Aviomarin works by exerting a Central Nervous System (CNS) depressant effect that targets the body's balance and chemical signaling centers. This is achieved through a mechanism of effect that involves the suppression of labyrinthine function (the inner ear's motion sensor) and the blocking of certain receptors in the brain linked to the vomiting reflex. This action dampens the excessive sensory input that causes disequilibrium and distress, offering general symptomatic management against nausea and vertigo.

Regulatory References

  1. NIH MedlinePlus Dimenhydrinate Information

What side effects are possible with Aviomarin?

The safety profile of Aviomarin (Dimenhydrinate) is strictly defined by its properties as a first-generation antihistamine, with potential side effects officially categorized by global regulatory authorities.

Officially Documented Adverse Reactions

The most frequently observed adverse reactions are categorized based on standard regulatory frequency classifications:

  • Very Common: The most prominent effects are related to Central Nervous System (CNS) depression, primarily including drowsiness and sedation.
  • Common: Adverse effects frequently reported include dizziness, headache, dry mouth, and blurred vision. Gastrointestinal disturbances such as nausea, vomiting, or constipation are also common.

Side effects are officially grouped into System-Organ Classes (SOCs), which include Nervous System Disorders, Gastrointestinal Disorders, Eye Disorders, and less commonly, Renal and Urinary Disorders (e.g., urinary retention).

Serious Reactions and Safety Context

Serious Adverse Reactions are rare but officially documented, including hypersensitivity reactions (anaphylaxis) and, in very rare instances, severe conditions like aplastic anemia.

The official labeling highlights several contextual safety patterns:

Safety Note Category Regulatory Statement
Time-Related Pattern Sedation and drowsiness are more pronounced at the beginning of treatment.
Older Adults There is an increased risk of effects like drowsiness, confusion, and urinary retention.
Children May experience paradoxical excitation (restlessness, insomnia) more often than adults.

Safety Restrictions are defined by contraindications listed in regulatory documents. These include a known hypersensitivity to the active substance or its components, as well as pre-existing conditions such as acute narrow-angle glaucoma and a history of convulsive disorders. Co-administration with other CNS depressants is noted to increase the risk of enhanced sedation.

Overdose and Emergency Response

Aviomarin overdose is characterized by severe anticholinergic toxicity and central nervous system (CNS) effects, which can range from marked CNS depression to stimulation. Documented manifestations include agitation, delirium, hallucinations, fixed/dilated pupils, dry mouth, and severe symptoms such as coma or respiratory depression.

Overdosage carries a significant risk of life-threatening systemic outcomes. Regulatory labeling notes the potential for seizures (convulsions), hypotension, and serious cardiac arrhythmias, including QRS-complex widening and QTc prolongation. Overdose in pediatric patients is a specific concern, carrying a noted increased risk of hallucinations, convulsions, and death.

Authorities explicitly state that patients showing severe signs—including loss of consciousness, hallucinations, seizures, or trouble breathing—must seek emergency medical attention immediately or call a poison control center. Management is defined as symptomatic and supportive treatment, typically requiring hospital monitoring, which includes continuous vital sign and ECG monitoring, and procedures such as the administration of activated charcoal. While no universal antidote is documented, treatment protocols address the specific manifestations and support the patient’s essential systems.

Therapeutic Uses of Aviomarin

What Aviomarin Treats: Main Uses and Benefits

Aviomarin, which contains the active substance dimenhydrinate, is commonly used for managing symptoms related to motion sickness (kinetosis). It is an antihistamine that is relevant in contexts marked by increased discomfort or tension when traveling, particularly symptoms related to systemic imbalance caused by movement. This makes it applicable within clinical settings that involve acute or disruptive symptom patterns, such as travel sickness.

Dimenhydrinate is specifically used to help with nausea, vomiting, and dizziness caused by motion sickness. The medicine supports patients during episodes of heightened discomfort and provides support that helps ease the overall symptom burden. It is commonly used to help with symptom clusters that may become intense or disruptive, specifically nausea, vomiting, and dizziness. This means it is applied in scenarios where additional management of discomfort is required, and it contributes to easing the overall symptom load during symptomatic phases.

Quick Fact: Relief for Symptoms related to systemic imbalance

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Aviomarin

The eligibility profile for Aviomarin (Dimenhydrinate) is strictly defined by government regulatory documents, focusing on absolute contraindications and conditional restrictions based on age and health status.

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents (12 years and older) are approved for standard use. Children aged 2 to 11 years are approved for use at age-adjusted doses.
Populations for whom use is contraindicated Patients with known hypersensitivity to dimenhydrinate, its components, or other antihistamines. Use is contraindicated in neonates (injectable form) and is explicitly prohibited for unsupervised use in children under 2 years of age in most OTC labeling.
Age-related eligibility rules The minimum age for general use is 2 years. Use in older adults (65 years and older) requires caution as they may be more susceptible to effects like dizziness.
Condition-specific eligibility rules Caution is mandatory for patients with conditions sensitive to anticholinergic effects, including narrow-angle glaucoma, prostatic hypertrophy causing difficulty urinating, pyloroduodenal obstruction, and certain cardiovascular diseases or seizure disorders.
Pregnancy and lactation eligibility status The drug is classified as Pregnancy Category B (FDA). It is excreted into human milk. Use during pregnancy or breastfeeding is conditional and must be determined by a healthcare professional.

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use this medicine by establishing absolute contraindications based on ingredient sensitivity, and conditional limitations based on age and pre-existing conditions that are sensitive to the drug’s anticholinergic effects. This structure formally defines the population boundaries, requiring caution for specific comorbid groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Aviomarin (Dimenhydrinate) based primarily on documented pharmacodynamic enhancement and specific co-administration restrictions.

Pharmacodynamic and Substance Interactions

Co-administration with Central Nervous System (CNS) depressants (such as sedatives, opioids, hypnotics, or anxiolytics) results in an officially documented additive effect, leading to potentiated sedation and potential impairment. Use of alcohol must be strictly avoided due to the enhanced risk of marked drowsiness and CNS depression.

Combining Dimenhydrinate with drugs possessing anticholinergic effects (e.g., tricyclic antidepressants) is noted to intensify adverse anticholinergic outcomes, such as dry mouth or urinary retention.

Contraindications and Constraints

The regulatory profile specifies formal restrictions, including the contraindication of co-administration with Monoamine Oxidase Inhibitors (MAOIs). A mandatory temporal separation is required, prohibiting the use of Dimenhydrinate during or within 14 days following the discontinuation of MAOI therapy. Concomitant use with any other preparation containing diphenhydramine is also prohibited.

Risk Masking and Population Notes

A critical interaction involves ototoxic drugs (e.g., aminoglycoside antibiotics), where Dimenhydrinate may officially mask the early symptoms of ototoxicity (like vertigo or tinnitus). The label notes that interaction effects are potentially more pronounced in elderly and pediatric populations. Furthermore, use is formally contraindicated in neonates and premature infants.

Mechanism of Action

Antagonism of Central Histamine and Acetylcholine Receptors

Dimenhydrinate's action begins by rapidly crossing into the brain to act as an antagonist at Histamine H1 and Muscarinic Acetylcholine receptors (mAChR), which are key targets in the brainstem. By blocking these receptors, the drug directly interferes with the flow of excitatory signals that transmit disequilibrium information from the inner ear's balance system to the medullary reflex pathways.


Suppression of Vestibular and Emetic Signaling Pathways

The combined receptor blockade achieves a functional suppression of the vestibular nuclei and the Vomiting Center (VC) in the medulla. This mechanism dampens the excessive neuronal firing caused by discordant motion signals, thereby preventing the physiological cascade that transforms sensory input into the emetic reflex. The effect results in modulation of output within these pathways.


Mechanistic Counteraction of CNS Depression

Dimenhydrinate is chemically structured as an equimolar salt, where the primary antagonist component (Diphenhydramine) is paired with 8-Chlorotheophylline. This secondary component acts as an Adenosine Receptor Blocker, which provides a mild stimulant effect that functionally counteracts the intense CNS depression inherent to the primary antagonist molecule. This synergy modulates the systemic consequences without altering the core suppressive mechanism itself.

Dosage and Administration Information

The use of Dimenhydrinate is characterized by specific timing, dosage limits, and administrative routes. The primary route of administration is oral, though intramuscular (IM), intravenous (IV), and rectal forms are utilized when the oral route is impractical.

For prophylaxis against motion sickness, the first dose is taken 30 minutes to 1 hour before exposure to motion begins. Doses are typically repeated on an as-needed (PRN) basis. The standard adult oral dose range is 50 mg to 100 mg, which may be repeated every 4 to 6 hours. However, the total daily intake must not exceed 400 mg in a 24-hour period for immediate-release preparations.

The medicine can be administered with or without food. Administration rules for specific populations vary; for instance, pediatric dosing is age-dependent, ranging from 12.5 mg to 50 mg per dose for children 2 to 12 years of age, with strict maximum daily limits. When the IV route is utilized, the solution must be diluted and injected slowly over at least two minutes. These procedural steps and dose limits govern the standardized use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aviomarin

Evidence for Use in Motion Sickness

This section will summarize the clinical and non-clinical research that has evaluated how symptoms change when Aviomarin (dimenhydrinate) was evaluated in the context of motion sickness, such as nausea, vomiting, and dizziness, across various modes of travel.

Aviomarin was studied for use in motion sickness across many research scenarios, including those focusing on symptoms associated with travel by sea, air, and road. These studies often involved situations conducted during periods of increased symptom activity and relevant in trials assessing short-term or episodic symptom patterns. Research examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort associated with motion.

Findings derived from this research describe patterns related to outcomes describing episodic or acute changes in symptoms when the compound was used preventatively before exposure to motion. Studies monitored changes measured during the study period, and research highlights changes measured during the study period in symptom intensity. However, the quality and design of these older studies varies across studies, meaning definitive conclusions about the size of the effect may not be possible. Research is ongoing to better contextualize how patients reported their experience in modern settings.


Evidence for Use in Other Causes of Nausea and Vomiting

This part will outline studies that have investigated Aviomarin in situations involving nausea and vomiting from other origins, excluding those specifically related to cancer chemotherapy, to clarify what situations outside of motion sickness were studied.

Research explored how symptoms changed in some settings involving nausea and vomiting from causes other than motion sickness. These settings explored conditions characterized by fluctuating or episodic manifestations of nausea. This research has primarily examined temporary physiological imbalance and studies focusing on episodes where symptoms become more noticeable.

The available evidence on this topic is limited and primarily consists of older studies or those with small sample sizes. Some studies observed patterns related to changes in outcomes related to systemic or functional imbalance; however, the findings were mixed and the evidence remains limited. The focus of much of the available research is on motion sickness, and research outside this primary area is not fully established.


Long-term Studies and Follow-up

Most research on Aviomarin involves use over defined time intervals that are typically short, reflecting its intended use for episodic or acute symptoms. Follow-up durations were limited in the key studies. What is known about prolonged use was observed in some studies that contribute to the broader evidence landscape, but long-term effects are not fully established. Information on whether patterns observed remain consistent or if outcomes reflecting daily functioning or activity level change with repeated use is insufficient. Certainty remains low regarding the use of Aviomarin beyond the short-term periods covered in most trials.


Evidence in Special Populations

Aviomarin was studied for use in children aged 6 to 14, and specific research has explored symptom patterns in this age group. However, data for certain groups remain insufficient. For instance, research examining older adults or individuals with conditions marked by functional limitations or significant pre-existing health concerns is limited. Results apply only to the populations studied; therefore, the data may not fully capture scenarios involving certain existing conditions.


What is Still Uncertain About Aviomarin

A significant area of uncertainty is the lack of comparative evidence against newer or alternative methods for addressing motion sickness. Much of the evidence is derived from settings with varying symptom burdens and older methodologies. Furthermore, sample sizes were modest in some key areas, and evidence quality varies across studies. The current evidence contributes to the broader evidence landscape but also clearly highlights what is known — and what is still uncertain — about Aviomarin's evidence.

Frequently Asked Questions (FAQ)

Common questions about Aviomarin (FAQ)

Q: How quickly does Aviomarin start working after taking it?

Official instructions for preventative use state the dose should be administered 30 minutes to 1 hour before motion exposure begins.

This timing, defined in regulatory documents, suggests that the substance is expected to be active within this specific window to provide protection against motion sickness symptoms.


Q: How long does the effect of Aviomarin usually last?

The duration of the drug's effect can be indirectly estimated from the official dosing schedule.

Regulatory documents indicate that doses are typically repeated every 4 to 6 hours as needed to maintain the anti-motion sickness effect.


Q: What happens if I accidentally take more Aviomarin than intended?

Taking an amount greater than the approved maximum daily dose is associated with serious risks defined in regulatory documents.

Overdosage may lead to severe symptoms, including profound drowsiness, confusion, hallucinations, convulsions, and potentially coma.


Q: Is it possible to take Aviomarin every day for a long trip?

Regulatory research summaries show that studies primarily evaluate the drug's effects over short, defined time intervals.

Consequently, official information on the effects of prolonged or daily use for extended periods is not fully established.


Q: Is Aviomarin available over the counter in most countries?

The active ingredient, Dimenhydrinate, is generally classified by regulatory authorities as an Over-the-Counter (OTC) drug.

This means it is typically available for purchase without a doctor's prescription.


Q: Can older adults use Aviomarin safely?

Use in older adults (age 65 and over) requires caution according to official warnings.

Regulatory documents specify that this population may be more susceptible to adverse effects like pronounced drowsiness, confusion, and urinary retention.


Q: Can Aviomarin be used safely by women who are breastfeeding?

Regulatory information confirms that small amounts of the drug are excreted into human milk.

Therefore, official advice states a decision must be made regarding whether to discontinue nursing or discontinue the drug.


Q: Is there evidence of Aviomarin being studied in pregnant people?

Dimenhydrinate is classified as Pregnancy Category B by the FDA.

This classification is supported by animal reproduction studies and clinical studies in pregnant people that have not indicated an increased risk of abnormalities.


Q: If I miss a dose of Aviomarin before a trip, is it still worth taking later?

General patient advice found in regulatory materials describes the pattern for a missed dose: it is generally administered as soon as possible, but is often omitted if the time for the next scheduled administration is near.


Q: What should I know about taking Aviomarin if I have kidney issues?

Caution is officially advised for patients with existing kidney impairment, as the drug's components are excreted by the kidneys.

Furthermore, use is formally contraindicated in individuals with severe kidney impairment.


Q: What should I know about taking Aviomarin if I have liver issues?

Official regulatory documents state that the drug's components are extensively metabolized by the liver.

Due to this process, use is formally contraindicated in patients with severe liver impairment.


Q: What kind of research has been done on the long-term safety of Aviomarin?

Research on Aviomarin primarily involves studies focusing on short-term, episodic use.

Regulatory documents explicitly state that the long-term safety and effects of the drug are not fully established.


Q: Does Aviomarin work by affecting the inner ear?

The mechanism of action involves dampening the signals transmitted from the inner ear's balance system (the labyrinth) to the brain.

This central nervous system effect helps to suppress the excessive neuronal firing that causes motion sickness.


Q: What are the signs that a side effect from Aviomarin is serious and needs medical attention?

A critical regulatory note is that Dimenhydrinate may mask the early symptoms of damage caused by certain other medicines known as ototoxic drugs (e.g., some antibiotics).

These masked symptoms can include vertigo (dizziness) or tinnitus (ringing in the ears).


Q: Is Aviomarin the same type of drug as Dramamine or other travel sickness pills?

The well-known American brand name Dramamine is a common trade name for the active ingredient, Dimenhydrinate.

Aviomarin is the same chemical compound sold under a different brand name, and both belong to the class of first-generation antihistamine anti-emetics.


Q: Is Aviomarin meant for motion sickness only, or can it be used for other things?

Approved indications are strictly defined as the prevention and treatment of nausea, vomiting, dizziness, and/or vertigo associated with motion sickness.

The official product information does not list formal indications for other specific causes of nausea.


Q: Can taking Aviomarin affect my ability to concentrate on work?

Regulatory warnings state that the drug may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks.

This includes tasks such as driving a vehicle or operating machinery.


Q: Is it true that taking Aviomarin at night can help with sleep?

Drowsiness and sedation are officially listed as very common side effects related to the drug's action as an antihistamine and central nervous system depressant.

While this effect is noted, official indications are limited to motion sickness.


Q: Can Aviomarin be crushed or split if it's too difficult to swallow?

For certain tablet formulations, the official regulatory labeling indicates that the tablet is scored.

A scored tablet is designed to allow it to be broken into two pieces for administration.


Q: Are there different forms of Aviomarin, like liquid or chewable tablets?

Dimenhydrinate is available in multiple dosage forms defined in product monographs.

These formulations include the standard oral tablets, as well as chewable tablets and oral solutions (liquid forms).


Q: Why do people sometimes use Aviomarin for mild anxiety or restlessness?

Drowsiness and sedation are officially listed as very common side effects of the drug.

The drug's mechanism involves central nervous system depression, which may lead to a feeling of calmness or lessened activity.


Q: Can Aviomarin affect blood pressure readings?

Official caution notes regarding use in older adults mention a risk of hypotension (low blood pressure).

Furthermore, hypertension (high blood pressure) has been noted in regulatory descriptions of severe overdosage, indicating a pharmacological effect on the cardiovascular system.


Q: Is it possible to become dependent on Aviomarin if used frequently?

Regulatory safety fact sheets indicate that no dependence or withdrawal effects have been reported when the drug is used according to the official recommended dosage guidelines.

How should Aviomarin be stored and disposed of?

The official regulatory profile for Aviomarin (Dimenhydrinate) defines specific storage and handling requirements necessary for maintaining product quality and safety.


Official Storage Conditions

The tablets must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). The product requires storage in a dry place and must be protected from excessive moisture.


Child Safety and Packaging Rules

Aviomarin must be kept out of the sight and reach of children and should remain in its original container. Do not use the medicine if the packaging or blister pack is torn or broken. Do not use the product past the printed expiration date.


Disposal Instructions

Unused or expired Dimenhydrinate must be disposed of in accordance with local regulations, often through authorized take-back programs. The medicine should not be discarded in wastewater or regular household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aviomarin found in:

A-Z Index: